EP1207906A4 - TREATMENT OF NON-HODGKIN LYMPHOMA PATIENTS WITH BONE MARROW WITH INVOLVEMENT OF ANTI-CD20 ANTIBODIES - Google Patents

TREATMENT OF NON-HODGKIN LYMPHOMA PATIENTS WITH BONE MARROW WITH INVOLVEMENT OF ANTI-CD20 ANTIBODIES

Info

Publication number
EP1207906A4
EP1207906A4 EP00965561A EP00965561A EP1207906A4 EP 1207906 A4 EP1207906 A4 EP 1207906A4 EP 00965561 A EP00965561 A EP 00965561A EP 00965561 A EP00965561 A EP 00965561A EP 1207906 A4 EP1207906 A4 EP 1207906A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
patients
treatment
bone marrow
hodgkins lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00965561A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1207906A1 (en
Inventor
William H Rastetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of EP1207906A1 publication Critical patent/EP1207906A1/en
Publication of EP1207906A4 publication Critical patent/EP1207906A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00965561A 1999-08-11 2000-07-25 TREATMENT OF NON-HODGKIN LYMPHOMA PATIENTS WITH BONE MARROW WITH INVOLVEMENT OF ANTI-CD20 ANTIBODIES Withdrawn EP1207906A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14828799P 1999-08-11 1999-08-11
US148287P 1999-08-11
PCT/US2000/040459 WO2001010462A1 (en) 1999-08-11 2000-07-25 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Publications (2)

Publication Number Publication Date
EP1207906A1 EP1207906A1 (en) 2002-05-29
EP1207906A4 true EP1207906A4 (en) 2005-07-06

Family

ID=22525101

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00965561A Withdrawn EP1207906A4 (en) 1999-08-11 2000-07-25 TREATMENT OF NON-HODGKIN LYMPHOMA PATIENTS WITH BONE MARROW WITH INVOLVEMENT OF ANTI-CD20 ANTIBODIES

Country Status (11)

Country Link
EP (1) EP1207906A4 (no)
JP (1) JP2003513012A (no)
CN (2) CN101259270A (no)
AU (1) AU784971B2 (no)
CA (1) CA2378646A1 (no)
HK (1) HK1048945A1 (no)
MX (1) MXPA02001398A (no)
MY (1) MY136635A (no)
NO (1) NO20020639L (no)
TW (1) TWI279233B (no)
WO (1) WO2001010462A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777970C (en) 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
PT3284753T (pt) 2002-10-17 2020-05-04 Genmab As Anticorpos monoclonais humanos contra cd20 para utilização no tratamento da esclerose múltipla
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
CA2519870A1 (en) 2003-04-09 2004-10-28 Genentech, Inc. Use of rituximab intravenous compositions to treat rheumatoid arthritis
JP5416338B2 (ja) 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
CA2526402A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
DK2348051T3 (en) 2003-11-05 2019-03-18 Roche Glycart Ag CD20 antibodies with increased fc receptor binding affinity and effector function
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
CN106075435A (zh) 2004-06-04 2016-11-09 健泰科生物技术公司 用于治疗多发性硬化的方法
BR122018016031B8 (pt) 2004-08-04 2021-07-27 Applied Molecular Evolution Inc processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada
WO2007014278A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
CN101267836A (zh) 2005-07-25 2008-09-17 特鲁比昂药品公司 单剂量cd20特异性结合分子的用途
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
SG10202005450PA (en) 2007-07-09 2020-07-29 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010074724A1 (en) 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
RU2639288C2 (ru) 2009-08-11 2017-12-20 Дженентек, Инк. Получение белков в культуральных средах без глутамина
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
EP2536279A4 (en) 2010-02-19 2013-07-24 Millennium Pharm Inc CRYSTALLINE FORMS OF SODIUM 4 - {[9-CHLORO-7- (2-FLUORO-6-METHOXYPHENYL) -5H-PYRIMIDO [5,4-D] [2] BENZAZEPHIN-2YL] AMINO} -2-METHOXYBENZOATE
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
EP3247395A1 (en) * 2015-01-23 2017-11-29 Immunomedics, Inc. Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
BR112017024610A2 (pt) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag anticorpos para receptor antitransferrina com afinidade especificada
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN114031689A (zh) 2015-10-02 2022-02-11 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
MX2019003029A (es) * 2016-09-16 2019-09-13 Nordic Nanovector Asa Tratamiento de linfoma no hodgkin usando lilotomab y 177lu-lilotomab satetraxetano.
CN108421048B (zh) * 2016-09-28 2021-04-20 首都医科大学附属北京世纪坛医院 纳米活性碳靶向药物递送系统、制备方法及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009160A1 (en) * 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
WO2001010460A1 (en) * 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of intermediate- and high-grade non-hodgkins lymphoma with anti-cd20 antibody
EP1207904B1 (en) * 1999-08-11 2008-03-05 Biogen Idec Inc. New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2091684T3 (es) * 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009160A1 (en) * 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
WO2001010460A1 (en) * 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of intermediate- and high-grade non-hodgkins lymphoma with anti-cd20 antibody
EP1207904B1 (en) * 1999-08-11 2008-03-05 Biogen Idec Inc. New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 20 September 2006 (2006-09-20), LEAHY MICHAEL F. ET AL: "Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.", Database accession no. NLM16940276 *
GREGORY S.A. ET AL: "Relationship of degree of bone marrow involvement with hematologic toxicity in patients with non-Hodgkin's lymphoma treated with tositumomab and iodine I 131 tositumomab", PROC AM SOC CLIN ONC, vol. 22, 2314, Retrieved from the Internet <URL:http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=100932> [retrieved on 20100107] *
JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 SEP 2006, vol. 24, no. 27, 20 September 2006 (2006-09-20), pages 4418 - 4425, ISSN: 1527-7755 *
NGUYEN D T ET AL: "IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients", EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 62, no. 2, February 1999 (1999-02-01), pages 76 - 82, XP001056722, ISSN: 0902-4441 *
See also references of WO0110462A1 *
TSAI D E ET AL: "Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation", BONE MARROW TRANSPLANTATION, vol. 24, no. 5, 1 September 1999 (1999-09-01), pages 521 - 526, XP002327600, ISSN: 0268-3369 *
WISEMAN ET AL: 'IDEC-Y2B8 radioimmunotherapy: Baseline bone marrow involvement and platelet count are better predictors of hematologic toxicity than dosimetry' BLOOD. vol. 92, no.10, suppl. 1, part 1-2, 15 November 1998, page 417A, Abstract# 1721 *
WISEMAN G. ET AL: "RADIOIMMUNOTHERAPY: BASELINE BONE MARROW INVOLVEMENT AND PLATELET COUNT ARE BETTER PREDICTORS OF HEMATOLOGIC TOXICITY THAN DOSIMETRY", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 92, no. 10, SUPPL. 01, 15 November 1998 (1998-11-15), pages 417A, XP001056771, ISSN: 0006-4971 *
WITZIG THOMAS E ET AL: "Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma", JOURNAL OF CLINICAL ONCOLOGY, vol. 17, no. 12, December 1999 (1999-12-01), pages 3793 - 3803, XP002327601, ISSN: 0732-183X *

Also Published As

Publication number Publication date
TWI279233B (en) 2007-04-21
JP2003513012A (ja) 2003-04-08
CN1373671A (zh) 2002-10-09
WO2001010462A1 (en) 2001-02-15
CN101259270A (zh) 2008-09-10
CN100389825C (zh) 2008-05-28
MY136635A (en) 2008-11-28
EP1207906A1 (en) 2002-05-29
AU7626000A (en) 2001-03-05
HK1048945A1 (en) 2003-04-25
AU784971B2 (en) 2006-08-10
NO20020639D0 (no) 2002-02-08
NO20020639L (no) 2002-04-11
MXPA02001398A (es) 2002-08-12
CA2378646A1 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
HK1048945A1 (en) Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
EP1227836A4 (en) TREATMENT OF NON-HODGKINS LYMPHOMAS MEDIUM AND HIGH MALIGNANCE GRADE WITH ANTI-CD20 ANTIBODIES
AUPQ893200A0 (en) Medical residue treatment
IL133571A0 (en) Medical instrument for treating biological tissue
PT1066838E (pt) Composição para a regeneração de tecidos ósseos
GB9926231D0 (en) Medical implants
PT1716853E (pt) Utiliza??o de et743 para o tratamento de cancro em seres humanos
AU138426S (en) An electrode for medical use
PL358848A1 (en) Bone treatment material
HUP0001699A2 (en) Arrangement for decanting of blood
PL340948A1 (en) Syringe, in particular that for taking blood samples from patients
EP1173470A4 (en) TREATMENT OF BONE DISORDERS BASED ON ADRENOMEDULLINE OR ADRENOMEDULLINE AGONISTS
AU5215300A (en) Dental treatment area
AU3177500A (en) Proteins for diagnosis and treatment of breast cancer
GB0014990D0 (en) Medical endoscope
GB0001443D0 (en) Medical endoscope
IL143990A0 (en) Bone stimulating factor
EP1202751A4 (en) MEDICAL STERILIZER
GB9904252D0 (en) Composition for the treatment of pain
GB2341099B (en) Clinical table for treatment of the spine
AUPQ421299A0 (en) Treatment of bone disorder
GB2341314B (en) Medical patient suspension apparatus
GB9903558D0 (en) Medical treatment
AU140446S (en) Tissue processing instrument
IL145242A0 (en) Treatment of hiatial hernia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020308

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20050523

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100729

18W Application withdrawn

Effective date: 20100729